title: Letter: persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD.
authors.forename: C
authors.initials: C
authors.lastname: Steenholdt
authors.forename: J
authors.initials: J
authors.lastname: Brynskov
authors.forename: K
authors.initials: K
authors.lastname: Bendtzen
mesh_terms: D000893:Anti-Inflammatory Agents / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000276:immunology*; D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology*; D001323:Autoantibodies / Q000097:blood*; D005260:Female; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D008297:Male; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001323:Autoantibodies; D014409:Tumor Necrosis Factor-alpha